Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
F Duffaud, O Mir, P Boudou-Rouquette… - The Lancet …, 2019 - thelancet.com
Background Regorafenib has proven activity in patients with pretreated gastrointestinal
stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to …
stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to …
[HTML][HTML] Chondrosarcoma: a rare misfortune in aging human cartilage? The role of stem and progenitor cells in proliferation, malignant degeneration and therapeutic …
Unlike other malignant bone tumors including osteosarcomas and Ewing sarcomas with a
peak incidence in adolescents and young adults, conventional and dedifferentiated …
peak incidence in adolescents and young adults, conventional and dedifferentiated …
MAPK/ERK signaling in osteosarcomas, Ewing sarcomas and chondrosarcomas: Therapeutic implications and future directions
C Chandhanayingyong, Y Kim, JR Staples, C Hahn… - Sarcoma, 2012 - Wiley Online Library
The introduction of cytotoxic chemotherapeutic drugs in the 1970's improved the survival
rate of patients with bone sarcomas and allowed limb salvage surgeries. However, since the …
rate of patients with bone sarcomas and allowed limb salvage surgeries. However, since the …
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
C Chevreau, A Le Cesne, I Ray‐Coquard, A Italiano… - Cancer, 2013 - Wiley Online Library
BACKGROUND There is no standard treatment for progressive epithelioid
hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the …
hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the …
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children's Oncology Group
AR Kim, BC Widemann, M Krailo… - Pediatric blood & …, 2015 - Wiley Online Library
Background Sorafenib is an oral small molecule inhibitor of multiple kinases controlling
tumor growth and angiogenesis. The purpose of the phase 2 study was to determine the …
tumor growth and angiogenesis. The purpose of the phase 2 study was to determine the …
Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself
QK Yang, T Chen, SQ Wang, XJ Zhang, ZX Yao - Angiogenesis, 2020 - Springer
Bone and soft tissue sarcomas are rare malignant tumors originated from mesenchymal
tissues. They harbor more than 50 distinct subtypes and differ in pathological features and …
tissues. They harbor more than 50 distinct subtypes and differ in pathological features and …
[HTML][HTML] Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind …
F Duffaud, A Italiano, E Bompas, M Rios… - European Journal of …, 2021 - Elsevier
Background This multi-cohort trial explored the efficacy and safety of regorafenib for patients
with advanced sarcomas of bone origin; this report details the cohort of patients with …
with advanced sarcomas of bone origin; this report details the cohort of patients with …
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid …
F Navid, SD Baker, MB McCarville, CF Stewart… - Clinical Cancer …, 2013 - AACR
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT),
pharmacokinetics, and pharmacodynamics of sorafenib, bevacizumab, and low-dose oral …
pharmacokinetics, and pharmacodynamics of sorafenib, bevacizumab, and low-dose oral …
Incidence and risk of xerosis with targeted anticancer therapies
J Valentine, VR Belum, J Duran, K Ciccolini… - Journal of the American …, 2015 - Elsevier
Background Many targeted therapies used in the treatment of cancer can lead to the
development of xerosis, but the incidence and relative risk of xerosis have not been …
development of xerosis, but the incidence and relative risk of xerosis have not been …
New therapeutic targets in soft tissue sarcoma
EG Demicco, RG Maki, DC Lev… - Advances in anatomic …, 2012 - journals.lww.com
Soft tissue sarcomas are an uncommon and diverse group of more than 50 mesenchymal
malignancies. The pathogenesis of many of these is poorly understood, but others have …
malignancies. The pathogenesis of many of these is poorly understood, but others have …